BEDMINSTER, NJ (
bulls are finding it more difficult to explain away the stock's weakness. Some of the rationalizations for weak Vascepa prescription numbers are bordering on the bizarre.
Steve Rosenman, the
uber-est of Amarin fans
, took to his
"Instablog" Wednesday to insist that real Vascepa prescriptions are likely 300-400 times the number being reported by IMS Health. How does Rosenman know this? Because people are spending time on Amarin's
Using web analytics you will learn that 47% of visitors to the site stay there and visit multiple pages. They visit for at least 2 minutes. These metrics far exceed industry averages.
If you further look at the hit count, you can make some pretty interesting assumptions, like if just 5% of visitors to the page signed up for Vascepa savings, you add 500 more prescriptions per week. 5% is pretty low for such highly targeted messaging and for something that will be free. Kick that to 30% and you see where I'm heading.
Actual scripts in the 300-400X area (vs. IMS) is likely what is going on now.
I'm looking forward to hearing Amarin executives boast about sticky web eyeballs on their next conference call.
-- Reported by Adam Feuerstein in Boston.